select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Neurofibromatoses-Pipeline Review, H1 2016

Neurofibromatoses-Pipeline Review, H1 2016


  • Products Id :- GMDHC8196IDB
  • |
  • Pages: 73
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Neurofibromatoses-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Neurofibromatoses-Pipeline Review, H1 2016', provides an overview of the Neurofibromatoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses

The report reviews pipeline therapeutics for Neurofibromatoses by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neurofibromatoses therapeutics and enlists all their major and minor projects

The report assesses Neurofibromatoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neurofibromatoses

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neurofibromatoses pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Neurofibromatoses Overview 7

Therapeutics Development 8

Pipeline Products for Neurofibromatoses-Overview 8

Pipeline Products for Neurofibromatoses-Comparative Analysis 9

Neurofibromatoses-Therapeutics under Development by Companies 10

Neurofibromatoses-Therapeutics under Investigation by Universities/Institutes 11

Neurofibromatoses-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Neurofibromatoses-Products under Development by Companies 14

Neurofibromatoses-Products under Investigation by Universities/Institutes 15

Neurofibromatoses-Companies Involved in Therapeutics Development 16

Alexion Pharmaceuticals, Inc. 16

Arno Therapeutics, Inc. 17

AstraZeneca Plc 18

CalAsia Pharmaceuticals, Inc. 19

Kolltan Pharmaceuticals, Inc. 20

Lixte Biotechnology Holdings, Inc. 21

Novartis AG 22

Pfizer Inc. 23

Neurofibromatoses-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AR-42-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

asfotase alfa-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

everolimus-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

FRAX-597-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

KTN-0158-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

LB-201-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

LB-205-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

OS-342-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

selumetinib sulfate-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules for Neurofibromatoses Type I-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules to Inhibit Hsp90-Alpha and TRAP 1 for Neurofibromatosis Type 2-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

sunitinib malate-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Neurofibromatoses-Dormant Projects 69

Neurofibromatoses-Discontinued Products 70

Neurofibromatoses-Product Development Milestones 71

Featured News & Press Releases 71

May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 71

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Figures

Number of Products under Development for Neurofibromatoses, H1 2016 8

Number of Products under Development for Neurofibromatoses-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Top 10 Targets, H1 2016 25

Number of Products by Stage and Top 10 Targets, H1 2016 25

Number of Products by Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Routes of Administration, H1 2016 29

Number of Products by Stage and Routes of Administration, H1 2016 29

Number of Products by Molecule Types, H1 2016 31

Number of Products by Stage and Molecule Types, H1 2016 31

List of Tables

Number of Products under Development for Neurofibromatoses, H1 2016 8

Number of Products under Development for Neurofibromatoses-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Neurofibromatoses-Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 16

Neurofibromatoses-Pipeline by Arno Therapeutics, Inc., H1 2016 17

Neurofibromatoses-Pipeline by AstraZeneca Plc, H1 2016 18

Neurofibromatoses-Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 19

Neurofibromatoses-Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 20

Neurofibromatoses-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 21

Neurofibromatoses-Pipeline by Novartis AG, H1 2016 22

Neurofibromatoses-Pipeline by Pfizer Inc., H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Stage and Target, H1 2016 26

Number of Products by Stage and Mechanism of Action, H1 2016 28

Number of Products by Stage and Route of Administration, H1 2016 30

Number of Products by Stage and Molecule Type, H1 2016 32

Neurofibromatoses-Dormant Projects, H1 2016 69

Neurofibromatoses-Discontinued Products, H1 2016 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alexion Pharmaceuticals, Inc.

Arno Therapeutics, Inc.

AstraZeneca Plc

CalAsia Pharmaceuticals, Inc.

Kolltan Pharmaceuticals, Inc.

Lixte Biotechnology Holdings, Inc.

Novartis AG

Pfizer Inc.

Neurofibromatoses Therapeutic Products under Development, Key Players in Neurofibromatoses Therapeutics, Neurofibromatoses Pipeline Overview, Neurofibromatoses Pipeline, Neurofibromatoses Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com